The Journal of Rheumatology最新文献

Predicting treatment outcomes in patients with psoriatic arthritis or axial spondyloarthritis: An artificial intelligence-driven approach. 预测银屑病关节炎或轴性脊柱炎患者的治疗结果：人工智能驱动的方法。

The Journal of Rheumatology Pub Date : 2025-10-15 DOI: 10.3899/jrheum.2025-0327

Asmir Vodenčarević,Jan Brandt-Jürgens,Sara Bär,Peter Kästner,Michaela Köhm,David Simon,Frank Behrens,Thomas Glassen,Benjamin Gmeiner,Daniel Peterlik,Uta Kiltz

{"title":"Predicting treatment outcomes in patients with psoriatic arthritis or axial spondyloarthritis: An artificial intelligence-driven approach.","authors":"Asmir Vodenčarević,Jan Brandt-Jürgens,Sara Bär,Peter Kästner,Michaela Köhm,David Simon,Frank Behrens,Thomas Glassen,Benjamin Gmeiner,Daniel Peterlik,Uta Kiltz","doi":"10.3899/jrheum.2025-0327","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0327","url":null,"abstract":"OBJECTIVETo develop machine learning (ML) models to predict the probability at baseline of achieving low disease activity (LDA) and high health-related quality of life (HRQoL) in patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated with secukinumab.METHODSAQUILA is an ongoing multicentre, prospective, non-interventional study assessing the effectiveness and safety of secukinumab in patients with active PsA or axSpA in Germany. Data from 1961 participants were used to develop ML models for predicting treatment outcomes. We investigated baseline prediction of achieving LDA and high HRQoL at Week 16 using binary ML algorithms, identifying main predictors for LDA and high HRQoL and their direction of influence. In addition, explainable artificial intelligence (XAI) estimated the importance and impact of each predictor, based on how it affected the change in individual patient predictions.RESULTSIn PsA, the main LDA predictors were Patient's Global Assessment, Physician's Global Assessment, pretreatment with biologic disease-modifying anti-rheumatic drugs (bDMARDs), tender joint count (TJC) and age; high HRQoL predictors were PsA impact of disease, Beck Depression Inventory (BDI), height, TJC and body mass index (BMI). In axSpA, the main LDA predictors were Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), pretreatment with bDMARDS, C-reactive protein, assessment of Spondyloarthritis International Society Health Index (ASAS-HI) and height; high HRQoL predictors were ASAS-HI, BDI, BMI, height and age.CONCLUSIONXAI provides significant value by enabling explanations of individual patient predictions and their visualizations. This modelling approach may help in the development of a clinical decision support system for patient management.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145296281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Green Space Exposure: A New Approach for the Prevention and Control of Rheumatoid Arthritis. 绿地暴露：预防和控制类风湿关节炎的新途径

The Journal of Rheumatology Pub Date : 2025-10-15 DOI: 10.3899/jrheum.2025-0583

Jessica Stanhope,Philip Weinstein,Catherine L Hill

引用次数: 0

Could Some Medical Developments Over the Last 60 Years Explain in Part Conditions That Led to the Current US Administration? 过去60年的一些医学发展能否部分解释导致现任美国政府的条件？

The Journal of Rheumatology Pub Date : 2025-10-15 DOI: 10.3899/jrheum.2025-0735

Juan Schmukler,Theodore Pincus

引用次数: 0

Central Nervous System Vasculopathy in Systemic Sclerosis Resolved by Vasodilator Therapy. 血管扩张剂治疗解决系统性硬化症的中枢神经系统血管病变。

The Journal of Rheumatology Pub Date : 2025-10-15 DOI: 10.3899/jrheum.2025-0333

Tomohiro Kato,Eisuke Takamasu

引用次数: 0

Burden of Disease and Drug Response for Patients with Rheumatoid Arthritis by Shared Epitope and Anti-Citrullinated Protein Antibody Status. 共享表位和抗瓜氨酸化蛋白抗体状态对类风湿关节炎患者疾病负担和药物反应的影响

The Journal of Rheumatology Pub Date : 2025-10-15 DOI: 10.3899/jrheum.2025-0445

Kristin Wipfler,Joshua F Baker,Harlan Sayles,Sang Hee Park,Keith Wittstock,Ted R Mikuls,Kaleb Michaud

{"title":"Burden of Disease and Drug Response for Patients with Rheumatoid Arthritis by Shared Epitope and Anti-Citrullinated Protein Antibody Status.","authors":"Kristin Wipfler,Joshua F Baker,Harlan Sayles,Sang Hee Park,Keith Wittstock,Ted R Mikuls,Kaleb Michaud","doi":"10.3899/jrheum.2025-0445","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0445","url":null,"abstract":"OBJECTIVETo characterize disease burden among adults with RA by both shared epitope (SE) and ACPA status, and to determine how their responses to abatacept, TNF inhibitors, and JAK inhibitors may differ.METHODSUtilizing data from two observational cohorts (FORWARD, VARA), individuals with RA were classified by SE/ACPA status. Outcomes included disease activity (PAS-II, RAPID3, DAS28), Rheumatic Disease Comorbidity Burden (RDCI), lifetime DMARD exposure, and healthcare utilization. Differences by SE/ACPA classification were determined with multiple linear regression. Response to DMARD initiation was assessed with linear regression for continuous measures of disease activity and logistic regression for achieving a change as large as the minimum clinically important difference.RESULTSA total of 3,243 individuals were included (FORWARD n=917, VARA n=2,326). Comorbidity burden among ACPA- individuals was higher than in ACPA+ in both cohorts (RDCI, SE+/ACPA+ vs SE-/ACPA-, B [95% CI]; FORWARD -0.35 [-0.65 to -0.05], p=0.02; VARA -0.35 [-0.63 to -0.08], p=0.01). In FORWARD there were significant differences in disease burden, including lower disease activity (PAS-II -0.77 [-1.10 to -0.44], p<0.001), lower healthcare utilization (rheumatology visits -0.18 [-0.35 to 0.0], p=0.046), and higher DMARD counts (0.43 [0.02 to 0.85], p=0.04) among SE+/ACPA+ individuals. ACPA+ abatacept initiators were more likely to experience clinically important improvements in PAS-II and DAS28, but RAPID3 was not significantly associated with abatacept response.CONCLUSIONOur results highlight important differences in disease burden by SE/ACPA status and suggest that ACPA status, rather than correlative SE status, may be the stronger predictor of abatacept response among individuals with RA.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"207 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145296284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multicenter Study of Secukinumab Uptitration in Axial Spondyloarthritis: Real-World Evidence. 轴型脊柱炎中Secukinumab提升的多中心研究：真实世界证据

The Journal of Rheumatology Pub Date : 2025-10-15 DOI: 10.3899/jrheum.2025-0102

Dalifer Freites Núñez,Adela Gallego,Alicia García Dorta,Andrea García-Valle,Marta Valero Expósito,Isabel De la Morena Barrio,Celia Arconada,Cristina Valero,Manuel Fernández-Prada,Marta López I Gómez,Antonio Álvarez de Cienfuegos,Rubén López-Sánchez,Álvaro García Martos

{"title":"Multicenter Study of Secukinumab Uptitration in Axial Spondyloarthritis: Real-World Evidence.","authors":"Dalifer Freites Núñez,Adela Gallego,Alicia García Dorta,Andrea García-Valle,Marta Valero Expósito,Isabel De la Morena Barrio,Celia Arconada,Cristina Valero,Manuel Fernández-Prada,Marta López I Gómez,Antonio Álvarez de Cienfuegos,Rubén López-Sánchez,Álvaro García Martos","doi":"10.3899/jrheum.2025-0102","DOIUrl":"https://doi.org/10.3899/jrheum.2025-0102","url":null,"abstract":"OBJECTIVETo evaluate the real-world effectiveness, treatment retention, and safety of secukinumab (SEC) uptitration to 300 mg in patients with axial spondyloarthritis (axSpA), including radiographic (r-axSpA) and nonradiographic (nr-axSpA) subtypes, with active disease despite receiving SEC 150 mg every 4 weeks.METHODSThis multicenter, retrospective study included patients with axSpA who had received SEC 150 mg for ≥ 3 months and had active disease (Axial Spondyloarthritis Disease Activity Score [ASDAS] ≥ 2.1) at the time of dose escalation. Patients were followed for up to 24 months after escalation. Effectiveness was assessed through changes in ASDAS over time. Treatment retention was analyzed using Kaplan-Meier curves, with factors associated with discontinuation explored by Cox regression. Safety outcomes were reported as incidence of adverse events (AEs).RESULTSAmong 106 patients (77 r-axSpA, 29 nr-axSpA), ASDAS significantly declined within 6 months and was sustained through 24 months. Median ASDAS decreased from 4.1 to 2.0 in patients with r-axSpA and from 4.1 to 2.0 in those with nr-axSpA. Overall, 85.9% of patients achieved ASDAS ≤ 2.1 at least once after escalation. Retention of SEC 300 mg was 87.8% at 6 months and 59.1% at 24 months, with no significant difference between subtypes (log-rank P = 0.48). HLA-B27 positivity showed a nonsignificant trend toward higher discontinuation risk. AE incidence was 15.79 per 100 patient-years, and AEs were mostly mild infections and cutaneous reactions. No new safety signals were identified.CONCLUSIONSEC uptitration to 300 mg was associated with sustained improvements in disease activity and favorable retention and safety in axSpA patients with active disease after receiving SEC 150 mg, supporting dose escalation as a clinically effective and safe strategy.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145296285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Type B Insulin Resistance: A Case Report of a Rare Complication of Systemic Lupus Erythematosus. B型胰岛素抵抗：1例罕见的系统性红斑狼疮并发症。

The Journal of Rheumatology Pub Date : 2025-10-15 DOI: 10.3899/jrheum.2025-0533

S Amara Ogbonnaya,Sandra Williams,Marissa Lightbourne,Rebecca J Brown

引用次数: 0

Spondylodiscitis Caused by Tropheryma whipplei: Report of 2 Cases. 惠氏滋养瘤致脊柱炎2例报告。

The Journal of Rheumatology Pub Date : 2025-10-15 DOI: 10.3899/jrheum.2025-0214

Pauline Preuss,Alice Tison,Grégoire Cormier,Xavier Puéchal

引用次数: 0

Cardiopulmonary Predictors of Mortality in Sjögren Disease: Insights for Clinical Risk Stratification. Sjögren疾病中死亡率的心肺预测因子：临床风险分层的见解。

The Journal of Rheumatology Pub Date : 2025-10-15 DOI: 10.3899/jrheum.2025-0461

Francesca Coppi,Gianluca Pagnoni,Anna Vittoria Mattioli,Francesco Fedele

引用次数: 0

Promising Imaging Methods for Assessment of Structural Progression in Axial Spondyloarthritis. 评估轴型脊椎关节炎结构进展的有前途的影像学方法。

The Journal of Rheumatology Pub Date : 2025-10-15 DOI: 10.3899/jrheum.2025-0100

Mikkel Østergaard,Jakob M Møller,Susanne J Pedersen,Kasper Gosvig,Simone T Willesen

引用次数: 0